Perioperative clotting factor replacement and infection in total knee arthroplasty

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia Vol. 18; no. 4; pp. 607 - 612
• Main Authors: WONG, J. M.-L., MANN, H. A., GODDARD, N. J.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01-07-2012
• Subjects: Arthroplasty, Replacement, Knee - adverse effects; Blood Coagulation Factors - administration & dosage; haemophilia; haemophilic arthropathy; Hemarthrosis - etiology; Hemarthrosis - surgery; Hemophilia A - complications; Hemophilia A - drug therapy; Hemophilia B - complications; Hemophilia B - drug therapy; Humans; knee; Perioperative Care; Retrospective Studies; Surgical Wound Infection - etiology; total knee arthroplasty
• ISSN: 1351-8216; 1365-2516
• DOI: 10.1111/j.1365-2516.2011.02728.x

Total knee arthroplasty, or replacement (TKR), is now the most commonly performed surgical procedure performed in adults with haemophilia. It is indicated when end‐stage haemophilic arthropathy results in intractable pain and reduced function. In patients with haemophilia, however, there has always been a concern about the high risk of infection, which carries with it potentially catastrophic consequences. The aims of this study were to review the case series of TKR for haemophilic arthropathy published in the medical literature, comparing the published infection rates and the differing clotting factor replacement regimes employed. Nineteen retrospective case series were identified; representing 556 TKR’s in 455 patients with an overall infection rate of 7.9%. Case series which maintained a high level of clotting factor replacement throughout the first two postoperative weeks, however, had an infection rate of 2.15%, significantly lower than that of case series using the clotting factor replacement regime currently recommended in the World Federation of Hemophilia guidelines (9.22%P = 0.00545). We believe this study supports the use of a high level clotting factor replacement regime, replacing clotting factors to maintain them at a higher level for a longer period of time than currently recommended in international guidelines.